… This stresses the concept that antigen loss should be anticipated in the design … CAR T cells
could mediate disease remission in B-ALL that is naive or resistant to anti-CD19 CAR T cell …

… T cells with chimeric antigen receptors (CARs). These … receptors combine the effector
functions of T lymphocytes and the ability of antibodies to recognize pre-defined surface antigens …

… receptor (TCR) signaling. Several decades of … on T cell performance. This knowledge
provides the foundation for chimeric antigen receptor T cell (CAR-T cell) technology, by which T …

… T cells transduced with a CD19-directed chimeric antigen receptor (… 10 6 to 20.6×10 6 CTL019
cells per kilogram of body weight. … antigen receptors are genetically engineered receptors …

… Cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome
(… with CAR T cells. This review summarizes the current understanding of CAR T-cell toxicity …

… Interleukin-6 receptor blockade with tocilizumab remains the mainstay pharmacologic …
activity of the CAR T cells. This review describes the toxicities caused by CAR T cells and reviews …

… We report outcomes among patients receiving CD19-directed CAR T cells for the treatment
of B-cell lymphomas who were followed for a median of 28.6 months (range, 3.5 to 37.9). In …

… CAR T cell therapies CAR T cell therapies are produced by collecting a patient’s T cells via
… , Cellectis is developing allogeneic CAR T cell therapies using healthy donor T cells that are …

… antigen receptors (CARs) for expression on T cells more than 25 years ago. When the CAR
is derived from an antibody, the resultant cell … with CD19 and CD20 CAR T cells, we are …

… for B-cell lymphomas, and CD30 for Hodgkin and T-cell lymphomas, are currently being
investigated in clinical trials. Centrally manufactured CAR T cells are … Chimeric antigen receptors …